Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22609290 | 0.88 | ALDH1A1 (0.47) | SRD5A2P2RX3ALDH1A1TSHR | |
| SCHEMBL23486577 | 0.85 | GRIA1 (0.47) | ALDH1A1TSHRGRIA1GRIA3GAA | |
| SCHEMBL22609324 | 0.81 | GRIA1 (0.48) | TSHRGRIA1GRIA3GAAMEN1 | |
| SCHEMBL23453720 | 0.81 | GRIA1 (0.48) | ALDH1A1GRIA1GRIA3 | |
| SCHEMBL23453735 | 0.76 | — | — | |
| SCHEMBL23453716 | 0.74 | PTGER4 (0.45) | GRIA1GRIA3 | |
| SCHEMBL17289118 | 0.71 | SRD5A2 (0.55) | SRD5A2P2RX3ALDH1A1FFAR1IDH1 | |
| SCHEMBL2557137 | 0.70 | GAA (0.57) | ALDH1A1TSHRGRIA1GRIA3GAA | |
| SCHEMBL29956891 | 0.69 | MAOA (0.52) | ALDH1A1TSHRGAAMEN1KMT2A | |
| SCHEMBL20507226 | 0.69 | KMT2A (0.58) | TSHRGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | ORFAN BIOTECH SL (ES) | 2021-06-10 | — | — | US | disclosed |
| EP-3731840-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | Orfan Biotech Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171503-A1 | GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF | PNPO, XDH, GLS | SRD5A2 679/4885P2RX3 430/4885ALDH1A1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.